The research report provides a Primary Achondrogenesis therapeutics Market 2020, on a global basis, offering a forecast and statistic in terms of revenue during the forecast period.Market report titled “Achondrogenesis Market Research Report – Forecast to 2023” is an expert analysis report explores the market by Research Methodology, Segmentation, Key Players, and Major Region in-depth.
Achondrogenesis Market-Highlights
Achondrogenesis is a genetic rare disease that affects cartilage and bone development. The condition is characterized by narrow chest, rounded abdomen, and extremely short limbs. Achondrogenesis includes various symptoms such as, abdominal distention, flat face, anteverted nares, frontal bossing, lethal skeletal dysplasia, hydropsfetalis, abnormal enchondral ossification, and many others.
According to the U.S National Library of Medicine, the incidence of 1A and 1B, whereas achondrogenesis type 2 occur in 1 in 40,000 to 60,000 newborns. Majorly three types of achondrogenesis are known and out of these three, type 1B (ACG1B) is most severe condition. According to an article published in GeneReviews book, it is found that SLC26A2 is the only mutated gene known to cause ACG1B.
ALSO READ https://marketmirror24.com/2019/05/global-achondrogenesis-market-size-analysis-on-expert-professional-research-and-industry-growth-outlook-2019-2023/
A number of factors such as, rise in facilities for patients affected by rare diseases, increasing awareness among people, increasing government assistance, and improvement in regulatory framework are propelling the growth of achondrogenesis market.
Presence of mutated gene in the family history is also fuelling up the market to a great extent. As per the information suggested by National Center for Advancing Translational Sciences (NCATS), achondrogenesis type 1A and type 1B occurs due to autosomal recessive inheritance which means each parent carry one copy of the mutated gene.
It is estimated that achondrogenesis market is expected to grow at a CAGR 3.9% during the forecast period of 2017-2023.
Achondrogenesis Market-Regional Analysis
The Americas dominate the achondrogenesis market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported as USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Achondrogenesis Market-Segmentation
The achondrogenesis market is segmented on the basis of type, diagnosis, and end-users.On the basis of type, market is segmented into surgery achondrogenesis type IA (Houston-Harris type), achondrogenesis type IA (Houston-Harris type), and achondrogenesis type II (Langer-Saldino type).
On the basis of diagnosis, market is classified into physical examination, molecular genetic testing, and biochemical testing. Physical examination is further classified into X-ray, ultrasound, and others. Molecular genetic testing is also further segmented into Chorionic Villus Sampling (CVS), aminocentesis, and others.
Achondrogenesis Market-Key Players
Cook
Thermo Fisher Scientific
CooperSurgical Inc.
Illumina, Inc.
Siemens AG
FUJIFILM Holdings Corporation
Koninklijke
Philips N.V.
Stryker
Toshiba Corporation
Invivoscribe
READ MORE https://www.marketresearchfuture.com/reports/achondrogenesis-market-4668
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services